DE60321953D1 - Neue synergistische zusammensetzung enthaltend roflumilast und formoterol - Google Patents

Neue synergistische zusammensetzung enthaltend roflumilast und formoterol

Info

Publication number
DE60321953D1
DE60321953D1 DE60321953T DE60321953T DE60321953D1 DE 60321953 D1 DE60321953 D1 DE 60321953D1 DE 60321953 T DE60321953 T DE 60321953T DE 60321953 T DE60321953 T DE 60321953T DE 60321953 D1 DE60321953 D1 DE 60321953D1
Authority
DE
Germany
Prior art keywords
formoterol
composition containing
synergistic composition
new synergistic
containing roflumilast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60321953T
Other languages
German (de)
English (en)
Inventor
Rolf Beume
Daniela Bundschuh
Norbert Kolassa
Degenhard Marx
Christian Weimar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Nycomed GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed GmbH filed Critical Nycomed GmbH
Application granted granted Critical
Publication of DE60321953D1 publication Critical patent/DE60321953D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DE60321953T 2002-11-27 2003-11-26 Neue synergistische zusammensetzung enthaltend roflumilast und formoterol Expired - Lifetime DE60321953D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02026505 2002-11-27
PCT/EP2003/013275 WO2004047829A1 (en) 2002-11-27 2003-11-26 New synergistic combination comprising roflumilast and formoterol

Publications (1)

Publication Number Publication Date
DE60321953D1 true DE60321953D1 (de) 2008-08-14

Family

ID=32338002

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60321953T Expired - Lifetime DE60321953D1 (de) 2002-11-27 2003-11-26 Neue synergistische zusammensetzung enthaltend roflumilast und formoterol

Country Status (31)

Country Link
US (1) US20060142308A1 (https=)
EP (1) EP1567139B1 (https=)
JP (1) JP2006508994A (https=)
KR (1) KR101071798B1 (https=)
CN (1) CN100346777C (https=)
AT (1) ATE399543T1 (https=)
AU (1) AU2003292120B2 (https=)
BR (1) BR0316451A (https=)
CA (1) CA2506962C (https=)
CO (1) CO5690570A2 (https=)
CY (1) CY1110369T1 (https=)
DE (1) DE60321953D1 (https=)
DK (1) DK1567139T3 (https=)
EA (1) EA009935B1 (https=)
ES (1) ES2309357T3 (https=)
HR (1) HRP20050579B1 (https=)
IL (1) IL168308A (https=)
IS (1) IS2575B (https=)
MA (1) MA27539A1 (https=)
ME (1) ME00489B (https=)
MX (1) MXPA05005437A (https=)
NO (1) NO334247B1 (https=)
NZ (1) NZ540659A (https=)
PL (1) PL216752B1 (https=)
PT (1) PT1567139E (https=)
RS (1) RS51081B (https=)
SI (1) SI1567139T1 (https=)
TN (1) TNSN05131A1 (https=)
UA (1) UA83018C2 (https=)
WO (1) WO2004047829A1 (https=)
ZA (1) ZA200503308B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
PT1606261E (pt) 2003-03-10 2010-01-11 Nycomed Gmbh Novo processo para a preparação de roflumilast
US8663694B2 (en) * 2005-03-16 2014-03-04 Takeda Gmbh Taste masked dosage form containing roflumilast
DE102005030733A1 (de) * 2005-07-01 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
EP2359826B1 (en) * 2006-07-05 2013-10-30 Takeda GmbH Combination of HMG-COA reductase inhibitor rosuvastatin with a phosphodiesterase 4 inhibitor, such as roflumilast, roflumilast-N-oxide for the treatment of inflammatory pulmonary diseases
WO2013077830A1 (en) * 2011-11-25 2013-05-30 Mahmut Bilgic Synergistilly active combinations of roflumilast and carmoterol
US20130172303A1 (en) * 2012-01-03 2013-07-04 Forest Laboratories Holdings Ltd. Roflumilast compositions for the treatment of copd
EP2948148B1 (en) 2013-01-28 2020-07-29 Incozen Therapeutics Pvt. Ltd. Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide
CN104800214A (zh) * 2014-01-27 2015-07-29 成都英诺新科技有限公司 一种罗氟司特吸入气雾剂复方及制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
ES2176252T3 (es) * 1993-07-02 2002-12-01 Altana Pharma Ag Benzamidas sustituidas con fluoro-alcoxi y su utilizacion como agentes inhibidores de fosfodiesterasas de nucleotidos ciclicos.
DE69835594T2 (de) * 1997-02-17 2007-08-16 Altana Pharma Ag Zusammensetzungen zur behandlung von irds oder ards die 3-(cyclopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy) benzamid und lungensurfactant enthalten
US6624181B1 (en) * 1997-02-28 2003-09-23 Altana Pharma Ag Synergistic combination
AU6823098A (en) * 1997-02-28 1998-09-18 Byk Gulden Lomberg Chemische Fabrik Gmbh Synergistic combination of pde inhibitors and adenylate cyclase agonists or guanyl cyclyse agonists
JP2002523452A (ja) * 1998-08-26 2002-07-30 スミスクライン・ビーチャム・コーポレイション 肺疾患の治療方法
US6303145B2 (en) * 1999-05-10 2001-10-16 Sepracor Inc. (S,R) formoterol methods and compositions
EP1212089B1 (en) * 1999-08-21 2006-03-22 ALTANA Pharma AG Synergistic combination of roflumilast and salmeterol
GB0103630D0 (en) * 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
JP4143413B2 (ja) * 2001-03-22 2008-09-03 グラクソ グループ リミテッド β2−アドレナリン受容体アゴニストとしてのホルムアニリド誘導体
PT1383786E (pt) * 2001-04-30 2008-12-30 Glaxo Group Ltd Derivados anti-inflamatórios de éster 17.beta-carbotioato de androstano com um grupo éster ciclíco na posição 17.alfa

Also Published As

Publication number Publication date
EA200500774A1 (ru) 2005-12-29
HRP20050579B1 (hr) 2014-01-31
TNSN05131A1 (en) 2007-05-14
WO2004047829A1 (en) 2004-06-10
AU2003292120B2 (en) 2010-01-21
PT1567139E (pt) 2008-10-01
MA27539A1 (fr) 2005-09-01
CN100346777C (zh) 2007-11-07
RS51081B (sr) 2010-10-31
RS20050382A (sr) 2007-08-03
CA2506962A1 (en) 2004-06-10
KR101071798B1 (ko) 2011-10-11
ATE399543T1 (de) 2008-07-15
CA2506962C (en) 2012-01-03
NO334247B1 (no) 2014-01-20
BR0316451A (pt) 2005-10-11
EP1567139B1 (en) 2008-07-02
UA83018C2 (uk) 2008-06-10
NO20052999L (no) 2005-06-17
US20060142308A1 (en) 2006-06-29
IS7898A (is) 2005-06-20
CY1110369T1 (el) 2015-04-29
KR20050085104A (ko) 2005-08-29
IL168308A (en) 2010-12-30
ZA200503308B (en) 2006-11-29
ME00489B (me) 2011-10-10
CO5690570A2 (es) 2006-10-31
PL216752B1 (pl) 2014-05-30
WO2004047829A8 (en) 2005-06-30
AU2003292120A1 (en) 2004-06-18
PL377732A1 (pl) 2006-02-06
MXPA05005437A (es) 2005-08-03
ES2309357T3 (es) 2008-12-16
IS2575B (is) 2010-02-15
EA009935B1 (ru) 2008-04-28
HRP20050579A2 (hr) 2006-04-30
DK1567139T3 (da) 2008-11-03
CN1713903A (zh) 2005-12-28
HK1081861A1 (en) 2006-05-26
JP2006508994A (ja) 2006-03-16
NZ540659A (en) 2007-05-31
EP1567139A1 (en) 2005-08-31
SI1567139T1 (sl) 2008-12-31

Similar Documents

Publication Publication Date Title
DE60331236D1 (de) Orale zusammensetzungen zur behandlung von diabetes
ATE320800T1 (de) Synergistische kombination von roflumilast und salmeterol
DK1587506T3 (da) Administration af capsaicinoider
MXPA05006670A (es) Administracion de capsaicinoides.
WO2004043341A3 (en) Treatment for hemorrhagic shock
CY1110369T1 (el) Νεος συνεργιστικος συνδυασμος ο οποιος περιεχει ροφλουμιλαστη και φορμοτερολη
MXPA05012358A (es) Combinacion farmaceutica que comprende modafinilo y otra droga.
DK1656131T3 (da) Anvendelse af betain til behandling claudicatio intermittens
CY1110368T1 (el) Συνεργιστικος συνδυασμος ο οποιος περιλαμβανει ροφλουμιλαστη και (r,r)-φορμοτερολη
TWI347845B (en) Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
DK1212072T3 (da) Farmaceutisk præparat omfattende eukalyptus- og orangeolie

Legal Events

Date Code Title Description
8364 No opposition during term of opposition